Bifogade filer
Guard Therapeutics receives its first regulatory approval for the phase 2b study POINTER
Kurs
+7,09%
Likviditet
0,47 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-02-20 | 08:30 | Bokslutskommuniké 2024 |
| 2024-11-13 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-10 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
| 2024-05-08 | - | Årsstämma |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-21 | - | Bokslutskommuniké 2023 |
| 2023-12-15 | - | Split GUARD 50:1 |
| 2023-11-10 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-10 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
| 2023-05-09 | - | Årsstämma |
| 2023-05-09 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-24 | - | Extra Bolagsstämma 2023 |
| 2023-02-22 | - | Bokslutskommuniké 2022 |
| 2022-12-13 | - | Extra Bolagsstämma 2022 |
| 2022-11-16 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-13 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
| 2022-05-12 | - | Årsstämma |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-22 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-11-08 | - | Extra Bolagsstämma 2021 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-14 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
| 2021-05-12 | - | Årsstämma |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-24 | - | Bokslutskommuniké 2020 |
| 2020-11-18 | - | Kvartalsrapport 2020-Q3 |
| 2020-09-07 | - | Extra Bolagsstämma 2020 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-15 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
| 2020-05-14 | - | Årsstämma |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-27 | - | Kvartalsrapport 2019-Q3 |
| 2019-10-23 | - | Extra Bolagsstämma 2019 |
| 2019-08-27 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-31 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
| 2019-05-29 | - | Årsstämma |
| 2019-05-21 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-20 | - | Bokslutskommuniké 2018 |
| 2019-01-24 | - | Extra Bolagsstämma 2018 |
| 2018-11-21 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-01 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
| 2018-05-31 | - | Årsstämma |
| 2018-05-23 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-23 | - | Bokslutskommuniké 2017 |
| 2017-11-22 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-24 | - | Kvartalsrapport 2017-Q1 |
| 2017-05-19 | - | Split GUARD 20:1 |
| 2017-04-28 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
| 2017-04-27 | - | Årsstämma |
| 2017-03-14 | - | Extra Bolagsstämma 2017 |
| 2017-02-22 | - | Bokslutskommuniké 2016 |
| 2016-11-18 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-19 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-03 | - | Extra Bolagsstämma 2016 |
| 2016-04-28 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
| 2016-04-27 | - | Årsstämma |
| 2016-04-22 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-19 | - | Bokslutskommuniké 2015 |
| 2015-11-02 | - | Extra Bolagsstämma 2015 |
| 2015-10-30 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-20 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-29 | - | Kvartalsrapport 2015-Q1 |
| 2015-05-18 | - | Årsstämma |
| 2015-04-29 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
| 2015-02-18 | - | Bokslutskommuniké 2014 |
| 2014-11-19 | - | Kvartalsrapport 2014-Q3 |
| 2014-10-13 | - | Extra Bolagsstämma 2014 |
| 2014-08-20 | - | Kvartalsrapport 2014-Q2 |
| 2014-04-14 | - | Kvartalsrapport 2014-Q1 |
| 2014-04-03 | - | Split GUARD 1:5 |
| 2014-03-26 | - | X-dag ordinarie utdelning GUARD 0.00 SEK |
| 2014-03-25 | - | Årsstämma |
| 2014-02-21 | - | Bokslutskommuniké 2013 |
| 2013-11-12 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-15 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-22 | - | Årsstämma |
| 2013-05-15 | - | Kvartalsrapport 2013-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Guard Therapeutics today announced that Health Canada has approved the company's application to include patients in Canada in its phase 2b clinical study of RMC-035 as a kidney protective treatment in open heart surgery.
”The positive news is an important milestone in our continued clinical development of RMC-035 in open heart surgery. At the same time, we are preparing parallel application processes for study initiation in a number of countries in Europe,” said Tobias Agervald, CEO of Guard Therapeutics.
The POINTER study is a randomized, double-blind and placebo-controlled phase 2b study of RMC-035 with the main purpose of establishing an optimal dosing regimen and precise target group for treatment prior to a pivotal phase 3 study. The study is expected to include a total of approximately 160 patients divided into two different dose arms of RMC-035 and a control arm (placebo).
The study's primary endpoint is change in renal function (estimated glomerular filtration rate, eGFR) from study start to 90 days after surgery, which corresponds to the planned follow-up period of the study participants. Patient recruitment is expected to begin in the third quarter of 2024 and last for approximately one year. Overall study results are expected to be available approximately 6 months after completion of patient recruitment.
About the indication – kidney injury in open heart surgery
The company's drug candidate RMC-035 aims to counteract kidney injury that occurs in connection with open heart surgery and ultimately to reduce the risk of an irreversible loss of kidney function and future end-stage kidney disease that requires dialysis treatment or a kidney transplant.
Open heart surgery carried out using a heart-lung machine mainly includes coronary artery by-pass graft (CABG) with or without surgery of the heart valves or the aortic root. This type of surgery often causes significant damage to the kidneys. An important cause of a such damage is reduced blood flow to and oxygenation of the kidneys (ischemia-reperfusion injury).
Hemolysis is another contributing cause, meaning that red blood cells are damaged, which in turn gives rise to kidney injury due to harmful breakdown products of the oxygen-carrying substance hemoglobin. Hemolysis occurs when blood is circulated outside the body, via the heart-lung machine, and following blood transfusions that are often given in connection with the procedure.
Additionally, as a result of lack of oxygen and hemolysis, a secondary inflammation often occurs which contributes to an ongoing injury process in the kidneys with the risk of scarring and permanent loss of kidney function.
About RMC-035
RMC-035 represents a completely new class of drugs (first-in-class) and consists of a recombinant and modified variant of the endogenous protein alpha-1-microglobulin. The investigational drug has the ability to protect cells and their mitochondria from damage caused by oxygen deprivation and elevated levels of the oxygen-binding and toxic protein heme. Favorable treatment effects of RMC-035 have been observed in several preclinical disease models. RMC-035 has a natural affinity for the kidneys and is primarily being developed as an intravenous kidney protective treatment for patients at high risk of developing acute kidney injury (AKI).
RMC-035 has obtained an Investigational New Drug (IND) clearance by the U.S. Food and Drug Administration (FDA) for the treatment of AKI in open-heart surgery. Additionally, RMC-035 has been granted Fast Track Designation by the FDA to reduce the risk of irreversible loss of kidney function, the need for dialysis treatment, or death after open-heart surgery in patients at elevated risk of AKI. Recent top-line results from the Phase 2 study AKITA demonstrated a statistically significant and clinically relevant favorable effect of RMC-035 on long-term kidney outcomes in this patient population. In addition to open-heart surgery, a second development program with RMC-035 was initiated with a recently completed Phase 1b clinical study in patients undergoing kidney transplantation.
For further information, please contact:
Tobias Agervald, CEO
Telephone: +46 8 670 65 51
E-mail: info@guardtherapeutics.com
About Guard Therapeutics
Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company’s investigational drug RMC-035 is being developed as a kidney protective treatment in connection with open heart surgery and kidney transplantation. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.
Certified Adviser is Svensk Kapitalmarknadsgranskning AB, www.skmg.se.